Instituto Multidisciplinario de Oncología - CIC - Clínica Viedma, Río Negro.
A través del Centro de Investigaciones Clínicas de la Clínica Viedma (CIC), en IMO llevamos adelante un programa científico en búsqueda de soluciones innovadoras frente a la problemática del cáncer. El CIC se enfoca en la investigación de ensayos clínicos y la traducción de sus resultados a la práctica clínica. IMO es parte del Grupo Argentino de Investigación Clínica en Oncología (GAICO) y de la Asociación Argentina de Oncología Clínica (AAOC.25 de mayo 174, Viedma, Río Negro
Websitehttp://www.imoviedma.com.ar
Select an option
I am a doctor
I am a sponsor
Specializations
Cáncer de pulmón
Cáncer de mama
Cáncer de riñón
Cáncer de vejiga
Cáncer colorrectal
Cáncer de ovarios
Cáncer gastrointestinal
Cáncer de próstata
Melanoma
Mieloma Múltiple
Tumores solidos avanzados
Cáncer de vía biliar
Cáncer cabeza-cuello
Our team
Authorities
Director - Principal InvestigatorRubén Darío Kowalyszyn
Medical staff
PI - Sub-InvestigadoraGabriela Guaygua Loayza
Sub-InvestigadoraHazel Barboza Zambrano
Legal and Administrative staff
Clinical Research CoordinatorRocio Riganti
Open studies
Lung cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations - TROPION-Lung08 - Daiichi Sankyo, Inc.See more
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations - TROPION-Lung08 - Daiichi Sankyo, Inc.See more
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) - DeLLphi-306 - AmgenSee more
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) - CodeBreaK 202 - AmgenSee more
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) - CodeBreaK 202 - AmgenSee more
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
Head and neck cancer
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma - JADE - GlaxoSmithKlineSee more
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients - MCLA-158-CL02 - Merus N.V.See more
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) - MCLA-158-CL03 - Merus N.V.See more
Bile Duct Cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer - JZP598-302 - HERIZON-BTC-302 - Jazz PharmaceuticalsSee more
Breast Cancer
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) - TroFuse-011 - Merck Sharp & Dohme LLCSee more
Gastroesophageal cancer
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer - HLX22-GC-301 - Shanghai Henlius BiotechSee more
Urothelial cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 - KEYNOTE-D78 - Seagen Inc.See more
Colorectal cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - AmgenSee more
Skin cancer
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) - PRISM-MEL-301 - Immunocore LtdSee more
